|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Vanderbilt University |
|---|---|
| Information provided by: | Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT00178828 |
Purpose
The purpose of this study is to understand changes in brain chemical signals when people take antidepressants called sertraline (Zoloft®) and bupropion (Wellbutrin SR, Zyban ®). Spinal fluid is used to measure chemical levels of dopamine, serotonin, and other chemicals thought to be involved in depression. The study has potential to help understand and treat depression.
| Condition | Intervention | Phase |
|---|---|---|
|
Depression |
Drug: sertraline Drug: bupropion |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment |
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37212 | |
| Principal Investigator: | Ronald M Salomon, MD | Vanderbilt University |
More Information
| Study ID Numbers: | 000373, 5 K23 MH001828-03 |
| Study First Received: | September 12, 2005 |
| Last Updated: | August 27, 2007 |
| ClinicalTrials.gov Identifier: | NCT00178828 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Depression antidepressant SSRI |
|
Dopamine Uptake Inhibitors Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Depression Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Depressive Disorder Serotonin Uptake Inhibitors Pharmacologic Actions Behavioral Symptoms |
Serotonin Agents Mental Disorders Therapeutic Uses Bupropion Mood Disorders Sertraline Dopamine Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |